Nanoviricides, Inc.

NNVC NYSE SEC CIK 1379006
Follow Nanoviricides Weekly email: filings, results

Financials

Reported figures only · latest: Q1 2027 USD · US GAAP
Revenue, last quarter $0
Net income −$5.7M −221.7% vs same quarter last year
EPS, diluted −$0.23 −130% vs same quarter last year
Operating cash flow −$3.6M −128.5% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
$0
Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$15M−$10M−$5M$0FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearRevenueNet income
FY26$0−$8.2M
FY25$0−$9.5M
FY24$0−$8.3M
FY23$0−$8.6M
FY22-−$8.1M
FY21-−$8.8M
FY20-−$13.4M
FY19-−$8.4M
FY18-−$8.6M
FY17-−$10.3M
FY16-−$10.7M
FY15-−$2.2M
FY14-−$13.6M
FY13-−$8.9M
FY12-−$6.2M
Free cash flowOperating cash flow minus capital expenditure
−$15M−$10M−$5M$0FY12FY14FY16FY18FY20FY22FY24FY26
Show the numbers
YearFree cash flow
FY26−$7.8M
FY25−$8.5M
FY24−$6.5M
FY23−$5.8M
FY22−$6.2M
FY21−$8.5M
FY20−$6.7M
FY19−$6.9M
FY18−$8M
FY17−$8.1M
FY16−$7.3M
FY15−$13M
FY14−$11.6M
FY13−$5.9M
FY12−$4.2M